|
시장보고서
상품코드
2152392
구제역 백신 시장 규모, 점유율 및 동향 분석 보고서 : 대상 동물별, 백신별, 유통 채널별, 지역별 및 부문별 전망(2026-2033년)Foot And Mouth Disease Vaccine Market Size, Share & Trends Analysis Report By Animal (Cattle, Sheep & Goat, Swine), By Vaccine (Modified/Attenuated Live), By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
세계의 구제역 백신 시장은 2025년에 27억 달러 규모에 달할 것으로 예상되며, 2026년 29억 달러에서 2033년에는 51억 달러로 확대되며, 2026-2033년 연평균 성장률(CAGR)은 약 8.8%를 기록할 것으로 전망됩니다.
아시아태평양이 시장을 주도하고 있으며, 2025년에는 매출 점유율의 45.0%를 차지했습니다. 가축 사육 두수의 증가와 축산물에 대한 수요 증가는 시장 성장에 기여하는 중요한 요인으로 작용하고 있습니다. 또한 급속한 세계화와 기후 변화에 따라 지난 수십 년간 가축 질병이 증가하고 있습니다. 반려동물과 가축의 안전한 헬스케어를 보장하기 위해 정부는 다양한 조치와 프로그램을 시행하고 있습니다. 그 결과, 수의용 백신 시장의 성장에 기여하고 있으며, 그중에서도 구제역(FMD) 백신이 큰 비중을 차지하고 있습니다.
인구 증가에 따라 우유, 닭고기, 달걀, 육류 등 동물성 제품에 대한 수요가 높아지고 있습니다. 백신은 가축의 손실을 최소화하고 그 안전성을 확보하는 데 도움이 되며, 이것이 예측 기간 중 시장 성장을 촉진할 것으로 보입니다. 인도 등 일부 국가에서의 우유 및 유제품 생산·소비 증가도 시장 성장에 더욱 기여할 것으로 예상됩니다.
개발도상국에서는 가축이 GDP의 중요한 구성 요소이기 때문에 효율적인 동물 헬스케어에 대한 수요가 증가하고 있으며, 이것이 예측 기간 중 시장 성장을 촉진할 것으로 전망됩니다. 예를 들어 2024년 7월 인도 재무부가 발표한 정보에 따르면 2022-23 회계연도 총부가가치(GVA)의 4.6%를 축산 부문이 차지했으며, 이로 인해 1인당 우유, 계란, 육류 공급량이 증가했습니다. 가축의 건강을 유지하기 위한 첨단 투약 및 백신 접종 프로그램의 도입으로 가축 사육 두수가 급속히 증가하고 있습니다.
다양한 정부 정책과 프로그램이 이 시장의 성장을 지원하고 있습니다. 미국 식량농업국(USDA) 및 세계동물보건기구(OIE)에 따르면 구제역(FMD)의 관리 및 근절을 통해 축산 부문의 생산성과 경제적 생산량을 향상시키고, 이를 통해 식량안보를 강화하고 농촌 지역의 소규모 농가를 지원하기 위해 ‘SEACFMD 2021-2025’가 출범했습니다. 정부 기관의 투자는 구제역 백신 생산을 지원하며 시장 성장을 지원해 왔습니다.
자주 묻는 질문
목차
제1장 조사 방법 및 범위
제2장 요약
제3장 구제역 백신 시장: 변수, 동향, 범위
- 시장 개요 및 향후 전망
- 시장 규모 및 성장 전망
- 시장 역학
- 구제역 백신 시장 분석 툴
제4장 구제역 백신 시장: 동물별 추정 및 동향 분석
- 구제역 백신 시장: 동물 이동 분석, 2025-2033년
- 소
- 양 및 염소
- 돼지
- 기타
제5장 구제역 백신 시장: 백신별 추정 및 동향 분석
- 구제역 백신 시장: 백신별 변동 분석, 2025년 및 2033년
- 변형형/약독 생백신
- 불활성화(킬드)
- 기타 백신(DNA 백신, 펩티드 백신)
제6장 구제역 백신 시장: 유통 채널별 추정 및 동향 분석
- 구제역 백신 시장: 유통 채널별 동향 분석, 2025-2033년
- 수의병원·클리닉
- 정부 기관
- 기타
제7장 구제역 백신 시장: 지역별 추정 및 동향 분석
- 구제역 백신 시장의 지역별 점유율, 2025-2033년
- 유럽
- 러시아
- 프랑스
- 아시아태평양
- 일본
- 중국
- 인도
- 한국
- 인도네시아
- 한국
- 태국
- 라틴아메리카
- 브라질
- 아르헨티나
- 중동 및 아프리카
- 남아프리카
- 사우디아라비아
- UAE
- 쿠웨이트
- 이집트
- 터키
제8장 경쟁 현황
- 주요 시장 진입 기업의 최근 동향 및 영향 분석
- 기업 분류
- 기업 히트맵 분석
- 기업 개요
- Merck & Co., Inc.
- Biogenesis Bago
- Zoetis Inc.
- Boehringer Ingelheim International GmbH
- Indian Immunologicals Limited
- Bayer AG
- Hester Biosciences Limited
- Inner Mongolia Biwei Antai Biotechnology Co., Ltd.
- Brilliant Bio Pharma Limited
- Biovet Private Ltd
The global foot and mouth disease vaccine market was valued at USD 2.7 billion in 2025 and is projected to grow from USD 2.9 billion in 2026 to USD 5.1 billion in 2033, at a CAGR of approximately 8.8% from 2026 to 2033. The Asia Pacific dominated the market, accounting for a revenue share of 45.0% in 2025. The increasing livestock population and demand for animal products are significant factors contributing to market growth. In addition, with rapid globalization and climate change, livestock diseases have been increasing over the past few decades. To ensure safe healthcare practices for companion animals and livestock, the government has undertaken various initiatives and programs. Thereby, contributing to the growth of the veterinary vaccine market, of which foot and mouth disease (FMD) vaccines capture a significant share.
The growing human population has driven the demand for animal products such as milk, chicken, eggs, and meat. Vaccines help minimize animal loss and ensure their safety, which is likely to drive market growth over the forecast period. The increasing production and consumption of milk and milk products in countries such as India are further expected to contribute to market growth.
In developing countries, livestock is a contributor to GDP; hence, there is increasing demand for efficient animal healthcare practices, which is expected to drive growth in this market over the forecast period. For instance, in July 2024, according to information published by the Ministry of Finance (India), 4.6% of total GVA in 2022-23 was contributed by the livestock sector, thereby boosting the per capita availability of milk, eggs, and meat. The livestock population has increased rapidly owing to the adoption of advanced medication and vaccination programs to maintain livestock health.
Various government initiatives and programs have boosted growth in this market. According to the Food and Agriculture Organization of the U.S. and the World Organization for Animal Health, SEACFMD 2021-2025 was launched to increase productivity and economic output in the livestock sector by managing and eradicating FMD, thereby enhancing food security and supporting rural smallholder farmers. Investments made by government institutions have supported the production of FMD vaccines and boosted the market growth.
Global Foot And Mouth Disease Vaccine Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global foot and mouth disease vaccine market report based on animal, vaccine, distribution channel, and region:
- Animal Outlook (Revenue, USD Billion, 2021 - 2033)
Cattle
Sheep and Goat
Swine
Others
- Vaccine Outlook (Revenue, USD Billion, 2021 - 2033)
Modified/ Attenuated Live
Inactivated (Killed)
Other Vaccines
- Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
Veterinary Hospitals & Clinics
Government Institutions
Others
- Regional Outlook (Revenue, USD Billion, 2021 - 2033)
Europe
- Russia
- France
Asia Pacific
- Japan
- China
- India
- South Korea
- Indonesia
- Thailand
Latin America
- Brazil
- Argentina
MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Egypt
- Turkey
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Foot & Mouth Disease Vaccine Market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
- 3.4. Foot & Mouth Disease Vaccine Market Analysis Tools
- 3.4.1. Porter's Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
- 3.4.1. Porter's Analysis
Chapter 4. Foot & Mouth Disease Vaccine Market: Animal Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Foot & Mouth Disease Vaccine Market: Animal Movement Analysis, 2025 & 2033 (USD Million)
- 4.3. Cattle
- 4.3.1. Cattle Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4. Sheep and Goat
- 4.4.1. Sheep and Goat Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Swine
- 4.5.1. Swine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Others
- 4.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Foot & Mouth Disease Vaccine Market: Vaccine Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Foot & Mouth Disease Vaccine Market: Vaccine Movement Analysis, 2025 & 2033 (USD Million)
- 5.3. Modified/ Attenuated Live
- 5.3.1. Modified/ Attenuated Live Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4. Inactivated (Killed)
- 5.4.1. Inactivated (Killed) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Other Vaccines (DNA vaccines, Peptide vaccines)
- 5.5.1. Other Vaccines (DNA vaccines, Peptide vaccines) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Foot & Mouth Disease Vaccine Market: Distribution Channel Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Foot & Mouth Disease Vaccine Market: Distribution Channel Movement Analysis, 2025 & 2033 (USD Million)
- 6.3. Veterinary Hospitals & Clinics
- 6.3.1. Veterinary Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4. Government Institutions
- 6.4.1. Government Institutions Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Others
- 6.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Foot & Mouth Disease Vaccine Market: Regional Estimates & Trend Analysis
- 7.1. Foot & Mouth Disease Vaccine Market Share, By Region, 2025 & 2033 (USD Million)
- 7.2. Europe
- 7.2.1. Europe Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.2.2. Russia
- 7.2.2.1. Russia Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.2.3. France
- 7.2.3.1. France Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3. Asia Pacific
- 7.3.1. Asia Pacific Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.2. Japan
- 7.3.2.1. Japan Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.3. China
- 7.3.3.1. China Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.4. India
- 7.3.4.1. India Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.5. South Korea
- 7.3.5.1. South Korea Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.6. Indonesia
- 7.3.6.1. Indonesia Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.7. South Korea
- 7.3.7.1. South Korea Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.8. Thailand
- 7.3.8.1. Thailand Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4. Latin America
- 7.4.1. Latin America Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.2. Brazil
- 7.4.2.1. Brazil Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Argentina
- 7.4.3.1. Argentina Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Middle East and Africa
- 7.5.1. Middle East and Africa Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. South Africa
- 7.5.2.1. South Africa Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Saudi Arabia
- 7.5.3.1. Saudi Arabia Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. UAE
- 7.5.4.1. Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Kuwait
- 7.5.5.1. Kuwait Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Egypt
- 7.5.6.1. Egypt Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Turkey
- 7.5.7.1. Turkey Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis by Key Market Participants
- 8.2. Company Categorization
- 8.3. Company Heat Map Analysis
- 8.4. Company Profiles
- 8.4.1. Merck & Co., Inc.
- 8.4.1.1. Participant's Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. Biogenesis Bago
- 8.4.2.1. Participant's Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. Zoetis Inc.
- 8.4.3.1. Participant's Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. Boehringer Ingelheim International GmbH
- 8.4.4.1. Participant's Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. Indian Immunologicals Limited
- 8.4.5.1. Participant's Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. Bayer AG
- 8.4.6.1. Participant's Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. Hester Biosciences Limited
- 8.4.7.1. Participant's Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. Inner Mongolia Biwei Antai Biotechnology Co., Ltd.
- 8.4.8.1. Participant's Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. Brilliant Bio Pharma Limited
- 8.4.9.1. Participant's Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Recent Developments/ Strategic Initiatives
- 8.4.10. Biovet Private Ltd
- 8.4.10.1. Participant's Overview
- 8.4.10.2. Financial Performance
- 8.4.10.3. Product Benchmarking
- 8.4.10.4. Recent Developments/ Strategic Initiatives
- 8.4.1. Merck & Co., Inc.
